Testsigma Releases Atto 2.0, Advancing Autonomous Testing for Modern Software Teams
SAN FRANCISCO, Nov. 21, 2025 /PRNewswire/ -- Testsigma, one of the fastest-growing AI-powered software testing platforms, has introduced Atto 2.0, a major advancement in autonomous testing that helps QA teams keep pace with the speed and complexity...
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its...
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
SYDNEY, Nov. 19, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized...
Artificial Intelligence Association of Hong Kong (AIHK) Annual Conference 2025: Building a Global Center of Excellence (CoE) for Artificial Intelligence
HONG KONG, Nov. 18, 2025 /PRNewswire/ -- The Artificial Intelligence Association of Hong Kong (AIHK) convenes its inaugural Annual Conference, celebrating a year of remarkable achievement and future vision as a Global Center of Excellence (CoE) for...
Locksley Enters into Sponsored Research Agreement with Columbia University to Develop Advanced Sustainable Processing Technologies for Rare Earth Elements (REE) and Critical Metal Recovery
SAN BERNARDINO, Calif., Nov. 17, 2025 /PRNewswire/ -- Locksley Resources, Ltd. (ASX: LKY; OTCQX: LKYRF) announced the company has formalized a research collaboration with Columbia University, one of the United States' premier institutions in...
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical...
Global Times: Xi stresses adopting high standards for building Hainan Free Trade Port
BEIJING, Nov. 9, 2025 /PRNewswire/ -- Chinese President Xi Jinping on Thursday stressed adopting high standards for building the Hainan Free Trade Port (FTP), the Xinhua News Agency reported. Xi, also general secretary of the Communist Party of...
Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence
The rebranding marks the first phase of Lunit's unified global identity, connecting breast health, AI detection, and precision oncology under one name. SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI...
Beko Day 2025: Celebrating the 10th Anniversary of the UN Sustainable Development Goals with Collective Action and Global Unity
ISTANBUL, Nov. 6, 2025 /PRNewswire/ -- Beko, a global leader in home appliances celebrated Beko Day with a powerful event of inclusion, and sustainability uniting over 50 thousand employees from 50 countries under one shared purpose: celebrating the...
Fosun Marks Eighth Year at CIIE, Guo Guangchang Calls for More Cutting-Edge Innovation
HONG KONG, Nov. 6, 2025 /PRNewswire/ -- On 5 November 2025, the 8th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). As a "full-attendance" exhibitor for eight consecutive years, Fosun,...